{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:19:21Z","timestamp":1791393561458,"version":"4.3.3"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03188-x","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:52:48Z","timestamp":1760619168000},"page":"1006-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anticoagulant therapy in patients with cancer and thrombocytopenia"],"prefix":"10.1007","volume":"58","author":[{"given":"Sebastian","family":"Szmit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"K\u0119pski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Mara\u0144da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz M.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zaborowska-Szmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"3188_CR1","unstructured":"Cancer Institute N Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0"},{"issue":"Suppl 2","key":"3188_CR2","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","volume":"133","author":"HA Liebman","year":"2014","unstructured":"Liebman HA (2014) Thrombocytopenia in cancer patients. Thromb Res 133(Suppl 2):S63\u2013S69","journal-title":"Thromb Res"},{"issue":"3","key":"3188_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1055\/s-0034-1371004","volume":"40","author":"K Lechner","year":"2014","unstructured":"Lechner K, Pabinger I, Obermeier HL, Knoebl P (2014) Immune-mediated disorders causing bleeding or thrombosis in lymphoproliferative diseases. Semin Thromb Hemost 40(3):359\u2013370","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"3188_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/jcm10061169","volume":"10","author":"A Leader","year":"2021","unstructured":"Leader A, Hofstetter L, Spectre G (2021) Challenges and advances in managing thrombocytopenic cancer patients. J Clin Med 10(6):1169","journal-title":"J Clin Med"},{"issue":"12","key":"3188_CR5","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","volume":"106","author":"S Lonial","year":"2005","unstructured":"Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC (2005) SUMMIT\/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106(12):3777\u20133784","journal-title":"Blood"},{"key":"3188_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.exphem.2020.12.001","volume":"94","author":"E Henry","year":"2021","unstructured":"Henry E, Arcangeli ML (2021) How hematopoietic stem cells respond to irradiation: similarities and differences between low and high doses of ionizing radiations. Exp Hematol 94:11\u201319","journal-title":"Exp Hematol"},{"issue":"1","key":"3188_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13287-024-03853-7","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen X, Wang X, Chen J, Du C, Wang J, Liao W (2024) Insights into ionizing radiation-induced bone marrow hematopoietic stem cell injury. Stem Cell Res Ther 15(1):222","journal-title":"Stem Cell Res Ther"},{"issue":"16","key":"3188_CR8","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.3390\/nu14163395","volume":"14","author":"Y Wu","year":"2022","unstructured":"Wu Y, Liao W, Chen J, Liu C, Zhang S, Yu K, Wang X, Chen M, Wang S, Ran X, Su Y, Cheng T, Wang J, Du C (2022) Phosphate metabolic inhibition contributes to irradiation-induced myelosuppression through dampening hematopoietic stem cell survival. Nutrients 14(16):3395","journal-title":"Nutrients"},{"issue":"5 Suppl","key":"3188_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1188\/17.CJON.S5.60-76","volume":"21","author":"K Brigle","year":"2017","unstructured":"Brigle K, Pierre A, Finley-Oliver E, Faiman B, Tariman JD, Miceli T, Myelosuppression (2017) Bone Disease, and acute renal failure: Evidence-Based recommendations for oncologic emergencies. Clin J Oncol Nurs 21(5 Suppl):60\u201376","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"3188_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/ejh.13595","volume":"106","author":"JL Shaw","year":"2021","unstructured":"Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA (2021) The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 106(5):662\u2013672","journal-title":"Eur J Haematol"},{"issue":"2","key":"3188_CR11","first-page":"170","volume":"20","author":"K Kilpatrick","year":"2021","unstructured":"Kilpatrick K, Shaw JL, Jaramillo R, Toler A, Eisen M, Sangar\u00e9 L, Soff GA (2021) Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials. Clin Colorectal Cancer 20(2):170\u2013176","journal-title":"Clin Colorectal Cancer"},{"issue":"17","key":"3188_CR12","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","volume":"7","author":"C Hsu","year":"2023","unstructured":"Hsu C, Patell R, Zwicker JI (2023) The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis. Blood Adv 7(17):4721\u20134727","journal-title":"Blood Adv"},{"issue":"3","key":"3188_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","volume":"112","author":"DE Gerber","year":"2008","unstructured":"Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 112(3):504\u2013510","journal-title":"Blood"},{"issue":"11","key":"3188_CR14","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","volume":"84","author":"Y Nishimoto","year":"2020","unstructured":"Nishimoto Y, Yamashita Y, Kim K, Morimoto T, Saga S, Amano H, Takase T, Hiramori S, Oi M, Akao M, Kobayashi Y, Toyofuku M, Izumi T, Tada T, Chen PM, Murata K, Tsuyuki Y, Sasa T, Sakamoto J, Kinoshita M, Togi K, Mabuchi H, Takabayashi K, Yoshikawa Y, Shiomi H, Kato T, Makiyama T, Ono K, Sato Y, Kimura T, COMMAND VTE Registry Investigators (2020) Risk factors for major bleeding during anticoagulation therapy in Cancer-Associated venous thromboembolism - from the COMMAND VTE registry. Circ J 84(11):2006\u20132014","journal-title":"Circ J"},{"issue":"7","key":"3188_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1056\/NEJMoa0904084","volume":"362","author":"SJ Slichter","year":"2010","unstructured":"Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362(7):600\u2013613","journal-title":"N Engl J Med"},{"issue":"6","key":"3188_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3324\/haematol.2014.118075","volume":"100","author":"SJ Stanworth","year":"2015","unstructured":"Stanworth SJ, Hudson CL, Estcourt LJ, Johnson RJ, Wood EM (2015) TOPPS study investigators. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica 100(6):740\u2013747","journal-title":"Haematologica"},{"issue":"10","key":"3188_CR17","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1182\/blood-2017-01-757930","volume":"130","author":"L Uhl","year":"2017","unstructured":"Uhl L, Assmann SF, Hamza TH, Harrison RW, Gernsheimer T, Slichter SJ (2017) Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood 130(10):1247\u20131258","journal-title":"Blood"},{"issue":"11","key":"3188_CR18","first-page":"1530","volume":"91","author":"K Webert","year":"2006","unstructured":"Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM (2006) The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 91(11):1530\u20131537","journal-title":"Haematologica"},{"issue":"1","key":"3188_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.16291","volume":"189","author":"PF Ypma","year":"2020","unstructured":"Ypma PF, van Geloven N, Kerkhoffs JLH, Te Boekhorst P, Zwaginga JJ, Beckers EAM, Brand A, van der Meer PF, Eikenboom JCJ (2020) The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study. Br J Haematol 189(1):171\u2013181","journal-title":"Br J Haematol"},{"issue":"9850","key":"3188_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","volume":"380","author":"H Wandt","year":"2012","unstructured":"Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, D\u00f6lken G, Klenner A, H\u00e4nel M, Herbst R, Junghanss C, Ehninger G (2012) Study alliance leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 380(9850):1309\u20131316","journal-title":"Lancet"},{"issue":"3","key":"3188_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","volume":"36","author":"CA Schiffer","year":"2018","unstructured":"Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, Omel JL, Rainey JM, Rebulla P, Rowley SD, Troner MB, Anderson KC (2018) Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 36(3):283\u2013299","journal-title":"J Clin Oncol"},{"issue":"12","key":"3188_CR22","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1111\/trf.14316","volume":"57","author":"JE Juskewitch","year":"2017","unstructured":"Juskewitch JE, Norgan AP, De Goey SR, Duellman PM, Wakefield LL, Gandhi MJ, Stubbs JR, Kreuter JD (2017) How do i \u2026 manage the platelet transfusion-refractory patient? Transfusion 57(12):2828\u20132835","journal-title":"Transfusion"},{"issue":"3","key":"3188_CR23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cam4.2008","volume":"8","author":"M D\u0142ugosz-Danecka","year":"2019","unstructured":"D\u0142ugosz-Danecka M, Szmit S, Og\u00f3rka T, Skotnicki AB, Jurczak W (2019) The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. Cancer Med 8(3):1103\u20131109","journal-title":"Cancer Med"},{"issue":"1","key":"3188_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.1980.03300270023023","volume":"243","author":"FH Gardner","year":"1980","unstructured":"Gardner FH, Helmer RE 3rd (1980) Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 243(1):35\u201337","journal-title":"JAMA"},{"issue":"5","key":"3188_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1600-0609.1985.tb02818.x","volume":"35","author":"HS Garewal","year":"1985","unstructured":"Garewal HS, Durie BG (1985) Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand J Haematol 35(5):497\u2013500","journal-title":"Scand J Haematol"},{"issue":"5","key":"3188_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1600-0609.1998.tb01046.x","volume":"60","author":"S Chakrabarti","year":"1998","unstructured":"Chakrabarti S, Varma S, Singh S, Kumari S (1998) Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? Eur J Haematol 60(5):313\u2013314","journal-title":"Eur J Haematol"},{"issue":"1","key":"3188_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/cncr.21958","volume":"107","author":"S Kalmadi","year":"2006","unstructured":"Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M (2006) Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 107(1):136\u2013140","journal-title":"Cancer"},{"issue":"1\u20132","key":"3188_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/10428199509059668","volume":"19","author":"O Shpilberg","year":"1995","unstructured":"Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I (1995) A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk Lymphoma 19(1\u20132):141\u2013144","journal-title":"Leuk Lymphoma"},{"issue":"8655","key":"3188_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0140-6736(89)90181-5","volume":"2","author":"G Avvisati","year":"1989","unstructured":"Avvisati G, ten Cate JW, B\u00fcller HR, Mandelli F (1989) Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 2(8655):122\u2013124","journal-title":"Lancet"},{"issue":"4","key":"3188_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1046\/j.1537-2995.1991.31491213301.x","volume":"31","author":"W Fricke","year":"1991","unstructured":"Fricke W, Alling D, Kimball J, Griffith P, Klein H (1991) Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion 31(4):345\u2013348","journal-title":"Transfusion"},{"issue":"3","key":"3188_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tmrv.2017.03.002","volume":"31","author":"J Montroy","year":"2017","unstructured":"Montroy J, Fergusson NA, Hutton B, Lavall\u00e9e LT, Morash C, Cagiannos I, Cnossen S, Fergusson DA, Breau RH (2017) The safety and efficacy of lysine analogues in cancer patients: a systematic review and meta-analysis. Transfus Med Rev 31(3):141\u2013148","journal-title":"Transfus Med Rev"},{"issue":"1","key":"3188_CR32","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(24)00317-X","volume":"12","author":"TREATT Trial Investigators","year":"2025","unstructured":"TREATT Trial Investigators (2025) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematol 12(1):e14\u2013e22","journal-title":"Lancet Haematol"},{"issue":"11","key":"3188_CR33","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1182\/blood.2022016308","volume":"140","author":"TB Gernsheimer","year":"2022","unstructured":"Gernsheimer TB, Brown SP, Triulzi DJ, Key NS, El Kassar N, Herren H, Poston JN, Boyiadzis M, Reeves BN, Selukar S, Pagano MB, Emerson S, May S (2022) Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. Blood 140(11):1254\u20131262","journal-title":"Blood"},{"issue":"5","key":"3188_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/17474086.2023.2201428","volume":"16","author":"AB Song","year":"2023","unstructured":"Song AB, Al-Samkari H (2023) Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia. Expert Rev Hematol 16(5):365\u2013375","journal-title":"Expert Rev Hematol"},{"key":"3188_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/JBM.S191790","volume":"10","author":"AZ Cheloff","year":"2019","unstructured":"Cheloff AZ, Al-Samkari H (2019) Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med 10:313\u2013321","journal-title":"J Blood Med"},{"issue":"1","key":"3188_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bja.2018.09.010","volume":"122","author":"A Nagrebetsky","year":"2019","unstructured":"Nagrebetsky A, Al-Samkari H, Davis NM, Kuter DJ, Wiener-Kronish JP (2019) Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J Anaesth 122(1):19\u201331","journal-title":"Br J Anaesth"},{"issue":"5","key":"3188_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","volume":"20","author":"EA Griffiths","year":"2022","unstructured":"Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L (2022) NCCN guidelines\u00ae insights: hematopoietic growth factors, version 1.2022. J Natl Compr Canc Netw 20(5):436\u2013442","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"3188_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7429","volume":"13","author":"GA Soff","year":"2024","unstructured":"Soff GA, Al-Samkari H, Leader A, Eisen M, Saad H (2024) Romiplostim in chemotherapy-induced thrombocytopenia: a review of the literature. Cancer Med 13(15):e7429","journal-title":"Cancer Med"},{"issue":"1","key":"3188_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/10781552231219003","volume":"31","author":"G Gurumurthy","year":"2025","unstructured":"Gurumurthy G, Kisiel F, Gurumurthy S, Gurumurthy J (2025) Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: a meta-analysis. J Oncol Pharm Pract 31(1):4\u201311","journal-title":"J Oncol Pharm Pract"},{"key":"3188_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101139","volume":"63","author":"H Al-Samkari","year":"2024","unstructured":"Al-Samkari H (2024) Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. Blood Rev 63:101139","journal-title":"Blood Rev"},{"issue":"1","key":"3188_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","volume":"22","author":"G Soff","year":"2024","unstructured":"Soff G, Leader A, Al-Samkari H, Falanga A, Maraveyas A, Sanfilippo K, Wang TF, Zwicker J (2024) Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy. J Thromb Haemost 22(1):53\u201360","journal-title":"J Thromb Haemost"},{"issue":"8","key":"3188_CR42","first-page":"CD010982","volume":"2016","author":"M Desborough","year":"2016","unstructured":"Desborough M, Estcourt LJ, Doree C, Trivella M, Hopewell S, Stanworth SJ, Murphy MF (2016) Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2016(8):CD010982","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3188_CR43","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","volume":"106","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ (2021) A multicenter study of Romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica 106(4):1148\u20131157","journal-title":"Haematologica"},{"issue":"1","key":"3188_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/hematology.2022000374","volume":"2022","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H (2022) Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem. Hematol Am Soc Hematol Educ Program 2022(1):286\u2013295","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"3188_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.24325","volume":"77","author":"BB Navi","year":"2015","unstructured":"Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MS, Panageas KS, DeAngelis LM (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77(2):291\u2013300","journal-title":"Ann Neurol"},{"issue":"8","key":"3188_CR46","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70(8):926\u2013938","journal-title":"J Am Coll Cardiol"},{"key":"3188_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2022.101072","volume":"41","author":"B Bungo","year":"2022","unstructured":"Bungo B, Chaudhury P, Arustamyan M, Rikhi R, Hussain M, Collier P, Kanj M, Khorana AA, Mentias A, Moudgil R (2022) Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA2DS2VASC score: CCHA2DS2VASC score. IJC Heart & Vasculature 41:101072","journal-title":"IJC Heart & Vasculature"},{"issue":"23","key":"3188_CR48","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","volume":"42","author":"E Grilz","year":"2021","unstructured":"Grilz E, Posch F, Nopp S, K\u00f6nigsbr\u00fcgge O, Lang IM, Klimek P, Thurner S, Pabinger I, Ay C (2021) Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis. Eur Heart J 42(23):2299\u20132307","journal-title":"Eur Heart J"},{"issue":"4","key":"3188_CR49","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","volume":"41","author":"SP Grover","year":"2021","unstructured":"Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N (2021) Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol 41(4):1291\u20131305","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"18","key":"3188_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183196","volume":"16","author":"J K\u0119pski","year":"2024","unstructured":"K\u0119pski J, Szmit S, Lech-Mara\u0144da E (2024) Time relationship between the occurrence of a thromboembolic event and the diagnosis of hematological malignancies. Cancers (Basel) 16(18):3196","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3188_CR51","first-page":"79","volume":"10","author":"M Zaborowska-Szmit","year":"2024","unstructured":"Zaborowska-Szmit M, Szmit S, Olszyna-Serementa M, Zajda K, Janowicz-\u017bebrowska A, Ja\u015bkiewicz P, Kowalski DM, Krzakowski M (2024) Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer. Cardiooncology 10(1):79","journal-title":"Cardiooncology"},{"issue":"14","key":"3188_CR52","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, B\u00fcller HR, S\u00f8rensen HT (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959\u20131969","journal-title":"Blood"},{"issue":"12","key":"3188_CR53","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, Fuereder T, Z\u00f6chbauer-M\u00fcller S, Preusser M, Pabinger I, Ay C (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137(12):1669\u20131678","journal-title":"Blood"},{"issue":"1","key":"3188_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8(1):11","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3188_CR55","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.3390\/curroncol30030230","volume":"30","author":"TF Wang","year":"2023","unstructured":"Wang TF, Carrier M (2023) Immune checkpoint inhibitors-associated thrombosis: incidence, risk factors and management. Curr Oncol 30(3):3032\u20133046","journal-title":"Curr Oncol"},{"issue":"8","key":"3188_CR56","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","volume":"133","author":"BB Navi","year":"2019","unstructured":"Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, Panageas KS, DeAngelis LM (2019) Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 133(8):781\u2013789","journal-title":"Blood"},{"issue":"11","key":"3188_CR57","doi-asserted-by":"publisher","first-page":"E468","DOI":"10.1002\/ajh.24526","volume":"91","author":"N Khanal","year":"2016","unstructured":"Khanal N, Bociek RG, Chen B, Vose JM, Armitage JO, Bierman PJ, Maness LJ, Lunning MA, Gundabolu K, Bhatt VR (2016) Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol 91(11):E468\u2013E472","journal-title":"Am J Hematol"},{"issue":"3","key":"3188_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/cncr.22434","volume":"109","author":"MG Sarkiss","year":"2007","unstructured":"Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, Champion JC, Swafford J, Shaw AD, Lenihan DJ, Durand JB (2007) Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 109(3):621\u2013627","journal-title":"Cancer"},{"issue":"2","key":"3188_CR59","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1634\/theoncologist.2016-0110","volume":"22","author":"A Feher","year":"2017","unstructured":"Feher A, Kampaktsis PN, Parameswaran R, Stein EM, Steingart R, Gupta D (2017) Aspirin is associated with improved survival in severely thrombocytopenic cancer patients with acute myocardial infarction. Oncologist 22(2):213\u2013221","journal-title":"Oncologist"},{"issue":"22","key":"3188_CR60","doi-asserted-by":"publisher","first-page":"10643","DOI":"10.1158\/0008-5472.CAN-06-2350","volume":"66","author":"J Rak","year":"2006","unstructured":"Rak J, Yu JL, Luyendyk J, Mackman N (2006) Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66(22):10643\u201310646","journal-title":"Cancer Res"},{"key":"3188_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-030-20315-3_2","volume":"179","author":"A Falanga","year":"2019","unstructured":"Falanga A, Schieppati F, Russo L (2019) Pathophysiology 1. mechanisms of thrombosis in cancer patients. Cancer Treat Res 179:11\u201336","journal-title":"Cancer Treat Res"},{"issue":"3","key":"3188_CR62","first-page":"171","volume":"17","author":"M Napolitano","year":"2019","unstructured":"Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, Federici AB, Rossi E, Santoro R, Siragusa S, Gruppo Italiano Malattie EMatologiche dell\u2019Adulto (GIMEMA) Working Party on Thrombosis and Hemostasis, Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis, De Stefano V, Falanga A, Tosetto A, Avvisati G, Carpenedo M, Federici AB, Marietta M, Napolitano M, Rossi E, Santoro C, Castaman G, Cerchiara E, Chistolini A, Contino L, Mazzucconi MG, Nichele I, Russo L, Santi R, Santoro RC, Siragusa S, Tagariello G (2019) Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus 17(3):171\u2013180","journal-title":"Blood Transfus"},{"issue":"41","key":"3188_CR63","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"},{"key":"3188_CR64","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2023.05.008","volume":"228","author":"J Goedegebuur","year":"2023","unstructured":"Goedegebuur J, Abbel D, Accassat S, Achterberg WP, Akbari A, Arfuch VM, Baddeley E, Bax JJ, Becker D, Bergmeijer B, Bertoletti L, Blom JW, Calvetti A, Cannegieter SC, Castro L, Chavannes NH, Coma-Auli N, Couffignal C, Edwards A, Edwards M, Enggaard H, Font C, Gava A, Geersing GJ, Geijteman ECT, Greenley S, Gregory C, Gussekloo J, Hoffmann I, H\u00f8jen AA, van den Hout WB, Huisman MV, Jacobsen S, Jagosh J, Johnson MJ, J\u00f8rgensen L, Juffermans CCM, Kempers EK, Konstantinides S, Kroder AF, Kruip MJHA, Lafaie L, Langendoen JW, Larsen TB, Lifford K, van der Linden YM, Mah\u00e9 I, Maiorana L, Maraveyas A, Martens ESL, Mayeur D, van Mens TE, Mohr K, Mooijaart SP, Murtagh FEM, Nelson A, Nielsen PB, Ording AG, \u00d8rskov M, Pearson M, Poenou G, Portielje JEA, Raczkiewicz D, Rasmussen K, Trinks-Roerdink E, Schippers I, Seddon K, Sexton K, Sivell S, Skj\u00f8th F, S\u00f8gaard M, Szmit S, Trompet S, Vassal P, Visser C, van Vliet LM, Wilson E, Klok FA, Noble SIR (2023) Towards optimal use of antithrombotic therapy of people with cancer at the end of life: a research protocol for the development and implementation of the SERENITY shared decision support tool. Thromb Res 228:54\u201360","journal-title":"Thromb Res"},{"issue":"1","key":"3188_CR65","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/eurjpc\/zwaa167","volume":"29","author":"D Richter","year":"2022","unstructured":"Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, Savelieva I, Fumagalli S, Bo M, Rocca B, Jensen MT, Pierard L, Sudano I, Aboyans V, Asteggiano R (2022) Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) aorta and peripheral vascular diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol 29(1):216\u2013227","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"3188_CR66","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s40262-023-01298-4","volume":"62","author":"C Grange","year":"2023","unstructured":"Grange C, Rioufol C, Souquet PJ, Assaad S (2023) Anti-coagulant treatment of cancer-associated thrombosis in frail patients: impact of frailties on the management of drug-drug interactions. Clin Pharmacokinet 62(11):1523\u20131531","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"3188_CR67","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1080\/10428194.2017.1306644","volume":"58","author":"DE Houghton","year":"2017","unstructured":"Houghton DE, Key NS, Zakai NA, Laux JP, Shea TC, Moll S (2017) Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. Leuk Lymphoma 58(11):2573\u20132581","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3188_CR68","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11239-017-1539-4","volume":"44","author":"BT Samuelson Bannow","year":"2017","unstructured":"Samuelson Bannow BT, Walter RB, Gernsheimer TB, Garcia DA (2017) Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis 44(4):442\u2013447","journal-title":"J Thromb Thrombolysis"},{"issue":"14","key":"3188_CR69","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","volume":"392","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, L\u00f3pez-N\u00fa\u00f1ez JJ, Otero-Candelera R, Le Gal G, Yeo E, Righini M, Robert-Ebadi H, Huisman MV, Klok FA, Westerweel P, Agnelli G, Becattini C, Bamias A, Syrigos K, Szmit S, Torbicki A, Verhamme P, Maraveyas A, Cohen AT, Ay C, Chapelle C, Meyer G, Couturaud F, Mismetti P, Girard P, Bertoletti L, Laporte S (2025) API-CAT Investigators.Extended Reduced-Dose Apixaban for Cancer-Associated venous thromboembolism. N Engl J Med 392(14):1363\u20131373","journal-title":"N Engl J Med"},{"key":"3188_CR70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.thromres.2024.01.012","volume":"235","author":"G Drozdinsky","year":"2024","unstructured":"Drozdinsky G, Arad N, Spectre G, Livneh N, Poran I, Raanani P, Falanga A, Ten Cate H, Gafter-Gvili A, Leader A (2024) Anticoagulation in cancer patients with atrial fibrillation and grade 3\u20134 thrombocytopenia. Thromb Res 235:92\u201397","journal-title":"Thromb Res"},{"issue":"10","key":"3188_CR71","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484\u20133488","journal-title":"Blood"},{"key":"3188_CR72","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.critrevonc.2018.09.014","volume":"132","author":"A Leader","year":"2018","unstructured":"Leader A, Ten Cate H, Spectre G, Beckers EAM, Falanga A (2018) Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps. Crit Rev Oncol Hematol 132:76\u201388","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"3188_CR73","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","volume":"103","author":"DP Cronin-Fenton","year":"2010","unstructured":"Cronin-Fenton DP, S\u00f8ndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, S\u00f8rensen HT (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997\u20132006. Br J Cancer 103(7):947\u2013953","journal-title":"Br J Cancer"},{"issue":"1","key":"3188_CR74","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1182\/hematology.2022000411","volume":"2022","author":"R Patell","year":"2022","unstructured":"Patell R, Zwicker JI, Evidence-Based, Minireview (2022) Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia. Hematol Am Soc Hematol Educ Program 2022(1):312\u2013315","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"3188_CR75","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","volume":"43","author":"S Mantha","year":"2017","unstructured":"Mantha S, Miao Y, Wills J, Parameswaran R, Soff GA (2017) Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis 43(4):514\u2013518","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"3188_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020953841","volume":"11","author":"P Craven","year":"2021","unstructured":"Craven P, Daly C, Sikotra N, Clay T, Gabbay E (2021) Dilemmas in anticoagulation and use of inferior vena cava filters in venous thromboembolism; a survey of respiratory physicians, haematologists and medical oncologists and a review of the literature. Pulm Circ 11(1):2045894020953841","journal-title":"Pulm Circ"},{"issue":"8","key":"3188_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081562","volume":"16","author":"P Kurzyna","year":"2024","unstructured":"Kurzyna P, Banaszkiewicz M, Florczyk M, K\u0119pski J, Pi\u0142ka M, K\u0119dzierski P, Ma\u0144czak R, Szwed P, Kasperowicz K, Wrona K, Doroszewski G, Torbicki A, Kurzyna M, Szmit S, Darocha S (2024) Safety and outcomes of inferior Vena Cava filter placement in oncology patients: a single-centre experience. Cancers (Basel) 16(8):1562","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3188_CR78","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3390\/biomedicines12102230","volume":"12","author":"AM Fioretti","year":"2024","unstructured":"Fioretti AM, La Forgia D, Scicchitano P, Brunetti ND, Inchingolo R, Tocchetti CG, Oliva S (2024) Inferior vena cava filter in cancer-associated thrombosis: a Vade mecum for the treating physicians: a narrative review. Biomedicines 12(10):2230","journal-title":"Biomedicines"},{"issue":"9","key":"3188_CR79","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jth.12338","volume":"11","author":"M Carrier","year":"2013","unstructured":"Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY (2013) Subcommittee on haemostasis and malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 11(9):1760\u20131765","journal-title":"J Thromb Haemost"},{"issue":"7","key":"3188_CR80","doi-asserted-by":"publisher","first-page":"e2011079","DOI":"10.1001\/jamanetworkopen.2020.11079","volume":"3","author":"S Balabhadra","year":"2020","unstructured":"Balabhadra S, Kuban JD, Lee S, Yevich S, Metwalli Z, McCarthy CJ, Huang SY, Tam A, Gupta S, Sheth SA, Sheth RA (2020) Association of inferior vena cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis. JAMA Netw Open 3(7):e2011079","journal-title":"JAMA Netw Open"},{"issue":"4","key":"3188_CR81","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11239-017-1557-2","volume":"44","author":"C Coombs","year":"2017","unstructured":"Coombs C, Kuk D, Devlin S, Siegelbaum RH, Durack JC, Parameswaran R, Mantha S, Deng K, Soff G (2017) Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. J Thromb Thrombolysis 44(4):489\u2013493","journal-title":"J Thromb Thrombolysis"},{"issue":"29","key":"3188_CR82","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","volume":"27","author":"A Falanga","year":"2009","unstructured":"Falanga A, Marchetti M (2009) Venous thromboembolism in the hematologic malignancies. J Clin Oncol 27(29):4848\u20134857","journal-title":"J Clin Oncol"},{"issue":"6","key":"3188_CR83","doi-asserted-by":"publisher","first-page":"e2317945","DOI":"10.1001\/jamanetworkopen.2023.17945","volume":"6","author":"KL Martens","year":"2023","unstructured":"Martens KL, Li A, La J, May SB, Swinnerton KN, Tosi H, Elbers DC, Do NV, Brophy MT, Gaziano JM, Lotfollahzadeh S, Chitalia V, Ravid K, Fillmore NR (2023) Epidemiology of cancer-associated venous thromboembolism in patients with solid and hematologic neoplasms in the veterans affairs health care system. JAMA Netw Open 6(6):e2317945","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3188_CR84","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","volume":"6","author":"P Prandoni","year":"2005","unstructured":"Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6(6):401\u2013410","journal-title":"Lancet Oncol"},{"issue":"4","key":"3188_CR85","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1177\/030089160409000405","volume":"90","author":"D Imberti","year":"2004","unstructured":"Imberti D, Vallisa D, Anselmi E, Moroni CF, Bert\u00e8 R, Lazzaro A, Bernuzzi P, Arcari AL, Cavanna L (2004) Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia. Tumori 90(4):390\u2013393","journal-title":"Tumori"},{"issue":"1","key":"3188_CR86","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/10428194.2015.1046864","volume":"57","author":"M Napolitano","year":"2016","unstructured":"Napolitano M, Valore L, Malato A, Saccullo G, Vetro C, Mitra ME, Fabbiano F, Mannina D, Casuccio A, Lucchesi A, Del Principe MI, Candoni A, Di Raimondo F, Siragusa S (2016) Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study. Leuk Lymphoma 57(1):116\u2013119","journal-title":"Leuk Lymphoma"},{"key":"3188_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.critrevonc.2018.02.003","volume":"124","author":"O Annibali","year":"2018","unstructured":"Annibali O, Napolitano M, Avvisati G, Siragusa S (2018) Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature. Crit Rev Oncol Hematol 124:41\u201350","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"3188_CR88","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/rth2.12111","volume":"2","author":"BR Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M (2018) Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost 2(4):664\u2013669","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"3188_CR89","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/jth.15748","volume":"20","author":"S Booth","year":"2022","unstructured":"Booth S, HaemSTAR N, Desborough M, Curry N, Stanworth S (2022) Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: the caveat multicenter prospective cohort. J Thromb Haemost 20(8):1830\u20131838","journal-title":"J Thromb Haemost"},{"issue":"24","key":"3188_CR90","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","volume":"5","author":"BJ Carney","year":"2021","unstructured":"Carney BJ, Wang TF, Ren S, George G, Al Homssi A, Gaddh M, Connolly GC, Shah VI, Bogue T, Bartosic A, Neuberg D, Baumann Kreuziger L, Zwicker JI (2021) VENUS network Investigators. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv 5(24):5546\u20135553","journal-title":"Blood Adv"},{"issue":"3","key":"3188_CR91","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11239-018-1621-6","volume":"45","author":"M Khan","year":"2018","unstructured":"Khan M, Cox TM, Nassif M, Alzubaidi MA, Garg N, Qiao W, Aung FM, Oo TH, Rojas-Hernandez CM (2018) Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a comprehensive cancer center. J Thromb Thrombolysis 45(3):377\u2013385","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"3188_CR92","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjh.13556","volume":"170","author":"HG Watson","year":"2015","unstructured":"Watson HG, Keeling DM, Laffan M, Tait RC, Makris M, British committee for standards in Haematology (2015) Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 170(5):640\u2013648","journal-title":"Br J Haematol"},{"issue":"2","key":"3188_CR93","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1055\/a-2365-8883","volume":"125","author":"LM Granat","year":"2025","unstructured":"Granat LM, Li H, Ondeck M, Osantowski B, Peysin C, Wilks M, Ferraro C, Sobecks R, Angelini D, Hamilton BK (2025) Venous thromboembolism post-allogeneic hematopoietic cell transplant: risk factors, incidence, and outcomes. Thromb Haemost 125(2):155\u2013162","journal-title":"Thromb Haemost"},{"issue":"2","key":"3188_CR94","doi-asserted-by":"publisher","first-page":"111.e1","DOI":"10.1016\/j.jtct.2024.10.016","volume":"31","author":"M Benfield","year":"2025","unstructured":"Benfield M, He J, Arnall J, Kaizen W, Jandrisevits E, Eboli-Lopes K, Dodd B, Grunwald MR, Avalos B, Copelan E, Patel JN (2025) Venous thromboembolism incidence and risk factors in patients undergoing hematopoietic stem cell transplantation. Transplant Cell Ther 31(2):111.e1-111.e10","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"3188_CR95","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1182\/bloodadvances.2017006130","volume":"1","author":"A Li","year":"2017","unstructured":"Li A, Davis C, Wu Q, Li S, Kesten MF, Holmberg LA, Gopal AK, Garcia DA (2017) Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv 1(12):707\u2013714","journal-title":"Blood Adv"},{"issue":"1","key":"3188_CR96","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/bloodadvances.2020003353","volume":"5","author":"KL Martens","year":"2021","unstructured":"Martens KL, da Costa WL, Amos CI, Davis C, Kesten M, Lee SJ, Zakai NA, Garcia DA, Li A (2021) High-2-low risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv 5(1):167\u2013175","journal-title":"Blood Adv"},{"issue":"9","key":"3188_CR97","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/ajh.26268","volume":"96","author":"KL Martens","year":"2021","unstructured":"Martens KL, Amos CI, Hernandez CR, Kebriaei P, da Costa WL Jr, Basom R, Davis C, Kesten M, Carrier M, Garcia DA, Lee SJ, Li A (2021) Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol 96(9):1137\u20131146","journal-title":"Am J Hematol"},{"issue":"7","key":"3188_CR98","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, B\u00fcller HR (2018) Hokusai VTE cancer Investigators.Edoxaban for the treatment of cancer-Associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"6","key":"3188_CR99","first-page":"1849","volume":"109","author":"R Patell","year":"2024","unstructured":"Patell R, Hsu C, Shi M, Grosso MA, Duggal A, Buller HR, Raskob G, Zwicker JI (2024) Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer. Haematologica 109(6):1849\u20131856","journal-title":"Haematologica"},{"issue":"1","key":"3188_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102684","volume":"9","author":"U Abbas","year":"2025","unstructured":"Abbas U, MacKenzie R, Khan U, Fatima R, Wang TF, Luo R, Hamm C, Cervi A (2025) Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review. Res Pract Thromb Haemost 9(1):102684","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"3188_CR101","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1055\/a-1777-4006","volume":"122","author":"R Lecumberri","year":"2022","unstructured":"Lecumberri R, Ruiz-Artacho P, Tzoran I, Brenner B, Farge-Bancel D, Ay C, Rosa V, Francisco I, Hern\u00e1ndez-Blasco LM, Trujillo-Santos J, Monreal M (2022) RIETE Investigators. Outcome of Cancer-Associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. Thromb Haemost 122(9):1594\u20131602","journal-title":"Thromb Haemost"},{"key":"3188_CR102","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.thromres.2023.05.012","volume":"227","author":"TF Wang","year":"2023","unstructured":"Wang TF, Carrier M, Carney BJ, Kimpton M, Delluc A (2023) Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis. Thromb Res 227:8\u201316","journal-title":"Thromb Res"},{"issue":"2","key":"3188_CR103","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","volume":"94","author":"I Kopolovic","year":"2015","unstructured":"Kopolovic I, Lee AY, Wu C (2015) Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol 94(2):329\u2013336","journal-title":"Ann Hematol"},{"issue":"4","key":"3188_CR104","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P (2021) American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974","journal-title":"Blood Adv"},{"issue":"5","key":"3188_CR105","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K (2023) ESMO guidelines Committee. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol 34(5):452\u2013467","journal-title":"Ann Oncol"},{"issue":"16","key":"3188_CR106","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41(16):3063\u20133071","journal-title":"J Clin Oncol"},{"issue":"7","key":"3188_CR107","doi-asserted-by":"publisher","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","volume":"22","author":"MB Streiff","year":"2024","unstructured":"Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin KY, Fogerty AE, Crestani NG, Gangaraju R, Rojas-Hernandez C, Goldhaber SZ, Ibrahim I, Kubal T, Leavitt AD, Lim M, Mann J, Mantha S, Morton C, Nester A, O\u2019Brien A, Ortel TL, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B (2024) Cancer-associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(7):483\u2013506","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"3188_CR108","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/jth.14015","volume":"16","author":"BT Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M (2018) Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 16(6):1246\u20131249","journal-title":"J Thromb Haemost"},{"issue":"8","key":"3188_CR109","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","volume":"6","author":"A Falanga","year":"2022","unstructured":"Falanga A, Leader A, Ambaglio C, Bagoly Z, Castaman G, Elalamy I, Lecumberri R, Niessner A, Pabinger I, Szmit S, Trinchero A, Ten Cate H, Rocca B (2022) EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere 6(8):e750","journal-title":"Hemasphere"},{"issue":"22","key":"3188_CR110","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2(22):3360\u20133392","journal-title":"Blood Adv"},{"issue":"5","key":"3188_CR111","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"12","key":"3188_CR112","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G (2006) LITE trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062\u20131072","journal-title":"Am J Med"},{"issue":"6","key":"3188_CR113","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/jth.12923","volume":"13","author":"CW Francis","year":"2015","unstructured":"Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK (2015) Treatment of venous thromboembolism in cancer patients with Dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost 13(6):1028\u20131035","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3188_CR114","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11239-015-1317-0","volume":"41","author":"MB Streiff","year":"2016","unstructured":"Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, McBane RD, Moll S, Ansell J (2016) Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 41(1):32\u201367","journal-title":"J Thromb Thrombolysis"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03188-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T19:01:46Z","timestamp":1766689306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03188-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":114,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3188"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03188-x","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The graphical abstract has been included in the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sebastian Szmit received speaker fee: Novartis, BMS, Bayer, Pfizer, Astra Zeneca. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}